title: International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease.
abstract: BACKGROUND
  Reflux Questionnaire (ReQuest), a newly developed gastro-oesophageal reflux disease-sensitive scale, can be used to reliably evaluate the effect of treatment on gastro-oesophageal reflux disease symptoms.
  
  
  OBJECTIVE
  International validation of this scale, in patients suffering from endoscopy-negative gastro-oesophageal reflux disease.
  
  
  METHODS
  In this open, multicentre and multinational clinical trial 840 endoscopy-negative gastro-oesophageal reflux disease patients received pantoprazole 20 mg daily for 28 days. The long and short versions of ReQuest were completed both in the pre-treatment and treatment phases. For scale development an item reduction analysis was performed. Internal consistency, test-retest reliability and responsiveness were calculated for psychometric analysis. Construct validity was evaluated by comparison with the Gastrointestinal Symptom Rating Scale and the Psychological General Well-being questionnaire by means of correlation coefficients.
  
  
  RESULTS
  Factor analyses confirmed the content validity of both long and short version of ReQuest. Psychometric calculations proved high internal consistency (Cronbach's alpha: 0.9), test-retest reliability [Intraclass Correlation Coefficient: 0.9 (long vs. long) and 0.8 (short vs. short)], and responsiveness (Responsiveness Index 320.3) of the scale, for which also good construct validity was achieved (correlation coefficient: Gastrointestinal Symptom Rating Scale 0.6; Psychological General Well-being -0.4).
  
  
  CONCLUSIONS
  ReQuest proved valid, reliable, and responsive in this multinational clinical trial to evaluate treatment response in endoscopy-negative gastro-oesophageal reflux disease patients.
authors.affiliation: District General Hospital, Rotherham, UK. bardhan.sec@rothgen.nhs.uk
authors.forename: K D
authors.initials: KD
authors.lastname: Bardhan
authors.forename: V
authors.initials: V
authors.lastname: Stanghellini
authors.forename: D
authors.initials: D
authors.lastname: Armstrong
authors.forename: P
authors.initials: P
authors.lastname: Berghöfer
authors.forename: G
authors.initials: G
authors.lastname: Gatz
authors.forename: H
authors.initials: H
authors.lastname: Mönnikes
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000328:Adult; D004334:Drug Administration Schedule; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000188:drug therapy*; D005773:Gastroscopy; D006801:Humans; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D011788:Quality of Life; D015203:Reproducibility of Results; D012720:Severity of Illness Index; D016037:Single-Blind Method; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000077402:Pantoprazole